Nafamostat Mesilate is not Appropriate as an Anticoagulant during Continuous Renal Replacement Therapy in Dogs

Miyama, Takako Shimokawa
Yoshioka, Chihiro
Minami, Koji
Okawa, Takumi
Hiraoka, Hiroko
Itamoto, Kazuhito
Mizuno, Takuya
Okuda, Masaru

We performed continuous renal replacement therapy (CRRT) in clinically healthy dogs (n=7) to evaluate the utility of nafamostat mesilate (NM) as an anticoagulant In Sol the 7 dogs. CRRT had to be discontinued before the target duration due to coagulation in the extracorporeal circuit. into which NM was administered constantly at the rate of 2 0-6 0 mg/kg per hour The mate of administration of NM was greater than the recommended dose of NM in humans Further, all the dogs so tercel vomiting during CRRT with NM infusion We therefore recommend that NM is not used as an anticoagulant during CRRT in dogs

JOURNAL OF VETERINARY MEDICAL SCIENCE

JAPAN SOC VET SCI

72

3

363

367

https://www.ncbi.nlm.nih.gov/pubmed/19959883
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000276321100019&DestApp=WOS_CPL